⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

August 7, 2024JAMA Dermatology

Long-Term Effectiveness and Reasons for Discontinuation of Dupilumab in Patients With Atopic Dermatitis

Celeste M. Boesjes Esmé Kamphuis Marlies de Graaf Lotte S. Spekhorst Inge Haeck Lian F. van der Gang Laura Loman Nicolaas P. A. Zuithoff Coco Dekkers Lisa P. van der Rijst Geertruida L. E. Romeijn Albert J. Oosting Antoni Gostynksi Anneke M. T. van Lynden‐van Nes Ron A. Tupker Anne-Moon van Tuyll van Serooskerken Annebeth Flinterman Klaziena Politiek Wouter R. H. Touwslager Wianda A. Christoffers Shiarra M. Stewart Marijke Kamsteeg Marie L. A. Schuttelaar Marjolein de Bruin‐Weller

View at Publisher

Ask AI

Bookmark

Share

Abstract

Limited data are available on the long-term effectiveness and safety of dupilumab for atopic dermatitis (AD) in daily practice.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Boesjes et al. (2024) studied this question.

synapsesocial.com/papers/68e5d23bb6db643587567f72 https://doi.org/10.1001/jamadermatol.2024.2517

View at Publisher

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Long-Term Effectiveness, Safety, and Survival of Dupilumab in Pediatric Atopic DermatitisCohort Study · 2026
2Short-, mid- and long-term efficacy of dupilumab in moderate-to-severe atopic dermatitis: a real-world multicentre Italian study of 2576 patients2024 · 16 citations
3Dupilumab provides sustained effectiveness on patient-reported outcomes and favorable safety in patients with moderate-to-severe atopic dermatitis: Up to 5-year results from the daily practice BioDay registry2024 · 35 citations
45PSQ-070 Dupilumab is a monoclonal antibody used for the treatment of atopic dermatitis. This study evaluates the effectiveness and persistence. Dupilumab presents good effectiveness and persistence2024
5Dupilumab in Patients with Atopic Dermatitis: A Multicentric, Long-Term, Real-World Portuguese Study2024 · 6 citations

More related papers

Dupilumab Safety and Efficacy up to 1 Year in Children Aged 6 Months to 5 Years with Atopic Dermatitis: Results from a Phase 3 Open-Label Extension Study2024
Long-Term Real-World Effectiveness and Response Trajectories of Dupilumab in Paediatric Atopic Dermatitis2026
Extended‐Interval Dosing and Discontinuation of Dupilumab in Atopic Dermatitis: A Real‐World Retrospective Study2026

More from JAMA Dermatology

Infantile HemangiomasWed,
Cancer Risk in Patients With Overall and Site-Specific Lichen PlanusWed,